Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared some papers on LinkedIn:
“Grateful for the chance to keynote at the Miami Precision Oncology Symposium.
I shared a vision that drives me in drug development: accelerating tissue‑agnostic drug development from today’s 10 approvals to 50–100 in the next 25-50 years—so every patient receives therapy based on molecular identity, not anatomic accident.
But the real highlight was the camaraderie- a remarkable gathering of leaders in precision oncology, with interactive sessions and conversations that pushed the field forward. Congratulations Manmeet Ahluwalia, Baptist Health, Miami Cancer Institute
for an amazing symposium.
Pleased to share my American Association for Cancer Research Journal Cancer Discovery perspective that expands on this vision.”
Title: Rethinking Cancer Drug Development through Tumor-agnostic Precision Medicine
Author: Vivek Subbiah
Read the Full Article.
Other articles featuring Vivek Subbiah on OncoDaily.
